Silvano Spinelli

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

EOS SpA engages in the manufacture of biopharmaceutical products. The company was founded by Silvano Spinelli, Gabriella Camboni, Ennio Cavalletti and Jacques Theurillat in June 2006 and is headquartered in Milan, Italy.

Biovelocita Srl (Biovelocita) is a venture capital firm founded in 2015 by Silvano Spinelli, Gabriella Camboni and Sofinnova Partners. The firm is headquartered in Milan, Italy.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Nephris Srl provides pre-clinical and research services for kidney diseases. The company is based in Milan, Italy. The Italian company was founded in 2021 by Paolo Fiorina, Francesca D'Addio. The CEO is Maria Gabriella Camboni.

Alia Therapeutics Srl engages in experimental research activities in the field of biotechnology. It specializes in the identification of new technologies for genome modification. The company was founded by Gianluca Petris, Antonio Casini, and Anna Cereseto and is headquartered in Trento, Italy.